Jakafi: Phase II data

Incyte stopped a sub-study of the double-blind, placebo-controlled, U.S. Phase II INCB18424-267 trial in about 373 patients with relapsed or refractory mCRC after a planned interim analysis showed that ruxolitinib plus Stivarga regorafenib did not produce “a sufficient level of efficacy to warrant continuation” in a subgroup of patients with high C-reactive protein (CRP) levels. The trial included an open-label Part 1 safety run-in and a double-blind Part 2, which included 2 sub-studies targeting patients with mCRC based on levels of systemic inflammation. Sub-study 1 included patients with CRP levels of >10 mg/L and sub-study 2 included patients with CRP levels of <=10 mg/L. ...